ReviewFrontiers in immunology2026
Neutrophil extracellular traps in pregnancy complications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophil extracellular traps (NETs) are fibrous, web-like structures released by activated neutrophils that consist of decondensed chromatin DNA coated with antimicrobial granular proteins. These structures play a dual role in host defense and pathology by effectively entrapping and eliminating pathogens. Under normal physiological conditions during pregnancy, appropriately regulated NET formation at the maternal-fetal interface functions as a crucial antimicrobial defense mechanism. However, emerging evidence indicates that excessive NET formation or defective clearance is strongly linked to the pathogenesis of several pregnancy complications such as preeclampsia, gestational diabetes mellitus, preterm birth, recurrent pregnancy loss, systemic lupus erythematosus, and obstetric antiphospholipid syndrome. This review systematically examines the regulatory mechanisms and pathophysiological contributions of NETs to these pregnancy complications. This review further explores the potential therapeutic mechanisms of common obstetric medications-including aspirin, metformin, low molecular weight heparin, hydroxychloroquine, and vitamin D-which may exert beneficial effects by suppressing NET formation or enhancing NET clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.